Yükleniyor... / Loading...
This study examines the effects of maple syrup on gut microbiota diversity and metabolic syndrome, compared with a placebo. It enrolled people with a body mass index between 23 and 40 who had at least one metabolic risk factor. The study was a non-phased study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * BMI between 23 and 40 kg/m2 * At least one of the following: Fasting triglyceride \> 1,35 mmol/L, Fasting insulinemia \> 42 pmol/L, fasting glycemia between 5,5 and 6,9 mmol/L and glycated haemoglobin (HbA1c) between 5.7 and 6.4 % * Understanding of spoken and written french * Accept to follow study instructions * If there is natural health product consumption, the dose and frequency of consumption must be stable since 3 months or more Exclusion Criteria: * Smoking * Any metabolic disorder requiring medication or affecting glucose or lipid metabolism * Aversion for maple taste * Allergy or intolerance for maple syrup or for an ingredient of the placebo syrup * Alcohol consumption of \> 2 drinks / day * Weight change \> 5% of body weight in the last 3 months * Being in a weight loss attempt * Antibiotics intake in the last 3 months * Regular probiotics intake in the last 3 months * Major surgical operation in the last 3 months or planned in the next months * Gastrointestinal malabsorption * Cirrhosis * Chronic kidney disease * Pregnant or breastfeeding women or women planning pregnancy in the next months * Participation in another clinical trial